Last reviewed · How we verify
Bipolar affective disorder, current episode manic
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Thorazine · Generic (originally Rhône-Poulenc/Sanofi)
- Lithium Citrate · Hikma
Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes. - Seroquel · AstraZeneca
- Epilim · Sanofi
- Saphris · Hisamitsu
Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C. - Vraylar · AbbVie
Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior. - Tegretol · Novartis AG (originally Geigy)
Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain. - Zyprexa · Eli Lilly
- Risperdal · Johnson & Johnson (Janssen)
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder. - Geodon · Pfizer Inc.
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class. - Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Carbamazepin · Enanta Pharmaceuticals, Inc
- Depakene · Generic (originally Abbott/AbbVie)
Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase. - Lithobid · Generic (multiple manufacturers)
- Lithium Carbonate
- Seroquel · University of Pittsburgh
- Quetiapin · Sykehuset Innlandet HF
- Risperdal · Ohio State University
- Zyprexa · Washington University School of Medicine
- Divalproex · University of Chicago
Clinical guidelines
- FDA label — not specified
Valproic acid is indicated for the treatment of acute mania associated with bipolar disorder.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Bipolar affective disorder, current episode manic patent landscape — cliff calendar, originator estates, attackable patents
- Bipolar affective disorder, current episode manic treatment landscape brief
- Bipolar affective disorder, current episode manic treatment updates RSS
Frequently asked questions about Bipolar affective disorder, current episode manic
What drugs treat Bipolar affective disorder, current episode manic?
Tracked treatments include Abilify, Thorazine, Lithium Citrate, Seroquel, Epilim, Saphris, Vraylar, Tegretol.
What is the treatment for Bipolar affective disorder, current episode manic?
Standard treatment for Bipolar affective disorder, current episode manic includes Abilify, Thorazine, Lithium Citrate, Seroquel, Epilim. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Bipolar affective disorder, current episode manic?
FDA label publishes guidelines for Bipolar affective disorder, current episode manic. 1 guideline references tracked.
Related
- Treatment landscape: Bipolar affective disorder, current episode manic patent cliff · Bipolar affective disorder, current episode manic CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Thorazine · Generic (originally Rhône-Poulenc/Sanofi)
- Treatment: Lithium Citrate · Hikma
- Treatment: Seroquel · AstraZeneca
- Treatment: Epilim · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing